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3D Imaging of Device Leads
“Taking the Lead With 3D”*Allan L. Klein, MD, Christine L. Jellis, MD, PHDCleveland, OhioPacemaker lead–associated tricuspid regurgitation
(TR) has been anecdotally described for many years,
but investigation has been limited to a small number
of observational studies (1). Overall, it seems that
worsening of TR is common after transvenous lead
placement (2). Perhaps the lack of formal research in
this area has stemmed from our previous inability to
adequately conﬁrm that device lead placement wasSee page 337a true determinant of TR severity via 2-dimensional
(2D) echocardiographic short-axis imaging (3). Se-
rial assessment of TR may also be difﬁcult because of
dependence on loading conditions. Minimal TR at
the time of implantation may appear more signiﬁ-
cant when the subject is not fasting and intracardiac
ﬁlling pressures have normalized. Limited options
available for lead repositioning or removal may have
also fostered complacence regarding this issue.
However, given the detrimental effect of signiﬁcant
TR on function (4) and survival (5) in a variety of
conditions (6,7), any opportunity to minimize iat-
rogenic TR should be considered.
Three-dimensional (3D) echocardiography pro-
vides better spatial orientation and en face imaging
of the tricuspid valve. The study by Mediratta et al.
(8) in this issue of iJACC makes timely use of this
technique to assess the mechanism of device lead–
associated TR. Perhaps surprisingly, only one pre-
vious small study has evaluated this concept (9).*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
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content of this paper to disclose.Although observational, this study illustrates the
beneﬁt of routine 3D image acquisition because the
investigators were able to identify 135 consecutive
patients with complete 2D and 3D transthoracic
echocardiographic imaging of the tricuspid valve
with a device lead in situ. Despite the retrospective
nature of the study, the ﬁndings show clinical rele-
vance and mirror the practicalities of serial imaging.
Technique feasibility with adequate 3D acquisition
as well as off-line analysis was relatively good, with
only 10% of subjects excluded from the analysis
because of poor image quality. This appears to be
better than would be typically expected in a busy
clinical echocardiography laboratory with off-line
processing capabilities. An advantage of this 3D
study over the previous study is that there was a
subgroup of subjects (n ¼ 53) with adequate 2D
echocardiograms before implantation, which facili-
tated direct comparison for worsening of TR after
implantation.
Despite this being a study of 3D echocardiogra-
phy application, this technique was reserved for
structural assessment of valve leaﬂets and lead loca-
tion only. Identiﬁcation and severity grading of TR
was performed via 2D color Doppler echocardiog-
raphy. This likely reﬂects that 3D color Doppler
imaging remains limited by low frame rates and
resultant poor image quality. The authors chose to
quantitate TR by using the largest vena contracta
(VC) width after imaging in multiple views. They
used mitral regurgitation VC classiﬁcation, because
VC grading for TR less than severe has not been
well deﬁned (10). A uniform Nyquist limit for VC
measurement was not speciﬁed. Although there is
consensus that this methodology is more accurate
than jet area (11), it is still reliant on the jet being
central and singular and may underestimate the
severity of TR in the setting of eccentric or multiple
jets. This may be problematic in this clinical setting,
Figure 1. Echocardiographic Imaging of a Pacing Lead Traversing the
Tricuspid Valve
(A) Two-dimensional right ventricular optimized 4-chamber transthoracic
apical view. (B) Tricuspid regurgitation associated with pacing lead impinge-
ment on color Doppler imaging. (C) The same apical long-axis view in a
3-dimensional view. (D) Three-dimensional short-axis view of the tricuspid
valve with leaﬂets labeled anterior (Ant), septal (Sept), and posterior (Post).
The pacing lead is indicated by the yellow arrow.
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349where impingement of one valve leaﬂet may result in
a highly eccentric regurgitant jet. Because of the
absence of conclusive data regarding TR quantiﬁ-
cation, the current guidelines stipulate that multiple
assessment parameters are preferred rather than a
single modality (11).
The most signiﬁcant results of this study include
that 46% of subjects had device lead leaﬂet
impingement prominently involving the posterior
and anterior leaﬂets. This appears to be consistent
with the typical position of the pacing lead tip
adjacent to the septum, meaning that maximum
curvature and lead displacement at the level of the
valve is away from the septal leaﬂet. TR was pre-
dictably more associated with device leads causing
valve impingement (VC: 0.6  0.3 cm) rather than
leads located centrally or in a commissural position
(VC: 0.3  0.3 cm) (Fig. 1). These ﬁndings were
corroborated by the subgroup analysis, which
showed that those with impinging leads had a
greater increase in TR from baseline than those with
nonimpinging leads, who had no appreciable
change. Interestingly, lead type did not have an
impact on the severity of TR; however, the majority
(78%) had implantable cardioverter-deﬁbrillator
(ICD) or biventricular ICD leads, leaving only a
small group with standard pacemaker leads for
comparison. This contradicts previous work showing
that ICD leads have higher rates of TR worsening
than standard pacing leads (2), perhaps due to
increased lead thickness and rigidity causing more
valve impingement. This discrepancy may reﬂect
underrepresentation of simple pacing leads in this
study (n ¼ 27; 22%). Biventricular quantiﬁcation
was omitted from this study but is clinically relevant.
The high proportion of ICD implantations implies
left ventricular dysfunction, so coexistent right ven-
tricular dysfunction and dilation may have predis-
posed these subjects to TR due to reduced leaﬂet
coaptation at baseline. Any alteration in valvular
geometry may have been sufﬁcient to potentiate TR
in a susceptible cohort. Increased pulmonary pres-
sures could likewise predispose certain subjects to
the development of TR after implantation, whereas
pre-existing TR may affect lead maneuverability.
The ﬁndings of this study suggest that the
mechanism of TR inducement appears to be lead
impingement or adherence rather than perforation
(n ¼ 2). This rate needs to be corroborated by au-
topsy or operative ﬁndings and may be center spe-
ciﬁc. 3D imaging resolution is not currently
adequate to differentiate between lead impingement
and adherence, while the propensity for lead-
associated endocardial inﬂammation appears to beunpredictable. Caution regarding lead extraction by
traction or laser must be taken to avoid signiﬁcant
valvular disruption and further worsening of TR as
well as issues related to sterility. Lead manipula-
tion may be more feasibly associated with other
concomitant cardiac surgery; however, resultant
increased procedural times may augment the risk of
infection. Some surgeons advocate securing the lead
in a commissural position at the time of tricuspid
valve annuloplasty and left-sided valve surgery.
However, this is not a realistic proposition for pa-
tients with isolated lead-associated TR. Ultimately,
there are currently no data to suggest that device lead
extraction or repositioning has any impact on TR
severity or outcomes in the total device population.
In this era of implantable device therapy, mini-
mization of iatrogenic TR must be a central goal.
Mediratta et al. (8) show useful application of 3D
transthoracic echocardiography in the identiﬁcation
of leaﬂet impingement as the predominant cause of
device lead–related TR. The long-term outcomes for
this type of valvular dysfunction remain unknown, as
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350does the beneﬁt of correction by lead extraction or
repositioning. As 3D echocardiography techniques
continue to evolve and improve, 3D color Doppler
imaging at higher frame rates will likely provide
complementary information regarding the real-time
relationship of TR to device lead location. Intra-
procedural 3D transesophageal or transthoracic echo-
cardiographic guidance may prove useful for optimal
lead placement and minimization of TR. However,randomized veriﬁcation against standard ﬂuoroscopy
is required, because protracted optimization of lead
positioning could add to implantation time, risk of
infection, and procedural costs.
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